Stored Saliva Cannabis Samples: Why a Two-Month Recommendation Can Coexist With Three-Month THC Data

A study found generally favorable THC stability in refrigerated oral-fluid samples for three months, yet recommended no more than two months when interpreting a broader cannabinoid panel. The difference reflects which analytes and acceptance criteria are being considered.

Authentic samples in a specified device

Researchers collected oral fluid with the Quantisal device after controlled cannabis smoking. Samples from seven frequent and eight occasional users were pooled separately for each participant and tested initially and after one, two and three months at 4°C.

The study evaluated THC, THC-COOH and several minor cannabinoids. It did not measure deterioration in every possible saliva container, buffer or shipping condition. The collection system was part of the tested workflow.

Some three-month results fell outside stability criteria

THC remained within the study’s stability range except for one participant’s result just below 80% of baseline at three months. Some THC-COOH and minor-cannabinoid measurements also fell below the criterion at that point.

Several occasional-user samples had analytes below quantification at baseline, leaving fewer evaluable samples for those compounds. A compound that could not be quantified initially does not provide an informative percentage-retention experiment.

A panel recommendation is not a single-analyte claim

The authors recommended a maximum two-month refrigerated interval to support the full panel, while describing the more favorable three-month THC observations separately. Those statements are compatible. The longer result should not be presented as a guarantee for all analytes.

Likewise, a result near an acceptance boundary does not justify an exact retrospective correction for a particular case. The study showed variability among participant pools rather than a single universal degradation factor.

What a reanalysis opinion needs

Obtain the device, buffer, actual temperature record, time to analysis and analyte-specific laboratory validation. The evidence is particularly relevant to delayed confirmatory or defense-requested reanalysis, but it does not certify specimens stored under different conditions. Stability concerns whether a concentration is preserved; it does not establish what that concentration meant for impairment when collected.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Karl B. Scheidweiler and colleagues. Long term stability of cannabinoids in oral fluid after controlled cannabis administration. Drug testing and analysis (2016). DOI: 10.1002/dta.2056.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Oral THC Affected Cognition Without a Parallel Symptom-Scale Increase in a Schizophrenia Study

An oral THC condition worsened selected cognitive outcomes without a significant parallel increase in measured psychotic symptoms several hours later. That combination of findings does not show that THC is harmless in schizophrenia or that all routes have identical effects. Several populations and treatment conditions The double-dummy laboratory study involved…

Spread the love

Read Article: Oral THC Affected Cognition Without a Parallel Symptom-Scale Increase in a Schizophrenia Study

CBD-Associated Liver Enzyme Elevations Occurred Without Reported Liver Symptoms

Healthy adults developed elevated liver enzymes during a four-week CBD trial despite not reporting corresponding liver-related symptoms. The finding shows why the absence of symptoms cannot substitute for the laboratory endpoint being studied. A repeated-dose randomized trial The trial involved 201 healthy participants overall and compared CBD at 5 mg/kg…

Spread the love

Read Article: CBD-Associated Liver Enzyme Elevations Occurred Without Reported Liver Symptoms

CBD–Terpene Sleep Trial: The Average Effect Was Smaller Than the Best-Responder Result

A CBD–terpene trial found a small average change in wearable-estimated sleep stages, while the largest reported improvements occurred in selected responders. Those responder figures should not be presented as the expected benefit for everyone with insomnia. A combined formulation and incomplete datasets The study used 300 mg CBD with eight…

Spread the love

Read Article: CBD–Terpene Sleep Trial: The Average Effect Was Smaller Than the Best-Responder Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us